2025 India Age-Related Mascular Degeneration Revenue Opportunities Report
Description
The 2025 India Age-Related Mascular Degeneration Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) market in India are Novartis AG, Roche (Genentech), Bayer AG, and Eyestem. Novartis markets drugs like Lucentis and Beovu targeting wet AMD and is expanding treatment options globally, including India. Roche offers Lucentis, Vabysmo, Susvimo, and Avastin (off-label), with global operations and recent Indian market expansions. Bayer’s Eylea (Aflibercept) leads the Indian AMD market segment with over 53% revenue share in 2021. Eyestem is an India-based biotech pioneering cell therapy (Eyecyte RPE) for dry AMD, recently approved for human trials in India, focusing on scalable, affordable regenerative treatments.
These companies contribute through innovative therapies, including anti-VEGF injections and emerging stem cell and gene therapies, making India a growing hub for AMD treatment. Eyestem is notable for developing advanced cell replacement therapies aiming to address the unmet needs of dry AMD patients in India. Roche and Novartis drive the market with widely used anti-VEGF drugs, while Bayer dominates the revenue share with Eylea. This competitive landscape supports India's growing AMD patient base with access to cutting-edge and affordable treatments.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Age-related Macular Degeneration (AMD) market in India are Novartis AG, Roche (Genentech), Bayer AG, and Eyestem. Novartis markets drugs like Lucentis and Beovu targeting wet AMD and is expanding treatment options globally, including India. Roche offers Lucentis, Vabysmo, Susvimo, and Avastin (off-label), with global operations and recent Indian market expansions. Bayer’s Eylea (Aflibercept) leads the Indian AMD market segment with over 53% revenue share in 2021. Eyestem is an India-based biotech pioneering cell therapy (Eyecyte RPE) for dry AMD, recently approved for human trials in India, focusing on scalable, affordable regenerative treatments.
These companies contribute through innovative therapies, including anti-VEGF injections and emerging stem cell and gene therapies, making India a growing hub for AMD treatment. Eyestem is notable for developing advanced cell replacement therapies aiming to address the unmet needs of dry AMD patients in India. Roche and Novartis drive the market with widely used anti-VEGF drugs, while Bayer dominates the revenue share with Eylea. This competitive landscape supports India's growing AMD patient base with access to cutting-edge and affordable treatments.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
